老年系统性红斑狼疮患者的多重用药与潜在不适当用药
该研究纳入206例年龄≥50岁的系统性红斑狼疮(SLE)患者,评估多重用药及潜在不适当药物(阿片类、苯二氮䓬类/Z类药物)的患病率与危险因素。结果显示72%患者使用≥5种药物,35%使用≥10种,31%使用苯二氮䓬类/Z类药物,24%使用阿片类;泼尼松使用、Charlson共病指数(CCI)评分及农村居住与多重用药相关,多重用药与苯二氮䓬类/Z类药物及阿片类使用显著相关。
要点
- 72%的老年SLE患者使用≥5种药物,35%使用≥10种药物
- 泼尼松使用、CCI评分和农村居住与多重用药风险增加相关
- 多重用药是处方苯二氮䓬类/Z类药物及阿片类的强标志
核心结论
- 该SLE队列中多重用药患病率高于马尼托巴省一般人群。
- 多重用药是处方苯二氮䓬类/Z类药物和阿片类的强标志。
研究设计与样本
- 研究纳入206例年龄≥50岁、符合ACR或SLICC分类标准并在三级风湿病诊所随访的SLE患者。
- 从马尼托巴省药物计划信息网络获取图表审查前4个月的处方填写信息,临床数据从电子病历中提取。
- 采用logistic回归分析评估多重用药(≥5种和≥10种药物两种定义)及潜在不适当用药与临床特征的相关性。
主要发现
- 148例(72%)填写≥5种药物,71例(35%)填写≥10种药物,63例(31%)使用苯二氮䓬类/Z类药物,50例(24%)使用阿片类。
- 在77例年龄≥65岁患者中,57例(74%)填写≥5种药物,26例(34%)填写≥10种药物。
- 泼尼松使用与≥5种药物多重用药的校正OR为3.70(95%CI 1.40-9.79)。
- CCI评分与多重用药的校正OR为1.62(95%CI 1.20-2.17),农村居住的校正OR为2.05(95%CI 1.01-4.18)。
- 多重用药与苯二氮䓬类/Z类药物使用的校正OR为4.35(95%CI 1.69-11.22),与阿片类使用的校正OR为6.75(95%CI 1.93-23.69);CCI评分与阿片类使用的校正OR为1.29(95%CI 1.08-1.54)。
关键数值与推荐
- 多重用药定义:使用≥5种药物或≥10种药物。
- 潜在不适当用药包括苯二氮䓬类/Z类药物和阿片类。
临床怎么用
- 对老年SLE患者应常规评估多重用药,尤其在使用泼尼松、共病负担高或农村居住者。
- 多重用药患者需警惕苯二氮䓬类/Z类药物和阿片类的处方,建议审查用药合理性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the prevalence and potential risk factors for polypharmacy and prescribing of the potentially inappropriate medications, opioids and benzodiazepines/Z-drugs, in older adults with systemic lupus erythematosus (SLE). METHODS: The study population comprised adults age ≥50 years meeting American College of Rheumatology or Systemic Lupus International Collaborating Clinics classification criteria followed at a tertiary care rheumatology clinic. Information on prescriptions filled in the 4 months preceding chart review was obtained from the Manitoba Drug Program Information Network. Clinical data, including age, sex, Charlson Comorbidity Index (CCI) score, Systemic Lupus Erythematosus Disease Activity Index 2000 score, prednisone use, SLE duration, and rural residence were abstracted from electronic medical records. Logistic regression analyses were performed to assess any association between polypharmacy (using 2 definitions: ≥5 and ≥10 medications), potentially inappropriate medication use, and clinical features. RESULTS: A total of 206 patients (mean age 62 years, 91% female, 36% rural) were included: 148 (72%) filled ≥5 medications, 71 (35%) filled ≥10 medications, 63 (31%) used benzodiazepines/Z-drugs, and 50 (24%) used opioids. Among the 77 patients age ≥65 years, 57 (74%) filled ≥5 medications, and 26 (34%) filled ≥10 medications, compared to 30% and 4%, respectively, of Manitobans age ≥65 years (National Prescription Drug Utilization Information System, 2016). The odds of polypharmacy were greater with prednisone use (adjusted odds ratio [OR] 3.70 [95% confidence interval (95% CI) 1.40-9.79] for ≥5 medications), CCI score (adjusted OR 1.62 [95% CI 1.20-2.17]), and rural residence (adjusted OR 2.05 [95% CI 1.01-4.18]). Odds of benzodiazepine/Z-drug use were increased with polypharmacy (adjusted OR 4.35 [95% CI 1.69-11.22]), and odds of opioid use were increased with polypharmacy (adjusted OR 6.75 [95% CI 1.93-23.69]) and CCI score (adjusted OR 1.29 [95% CI 1.08-1.54]). CONCLUSION: The prevalence of polypharmacy in this SLE cohort was higher than in the general Manitoban population. Polypharmacy is a strong marker for use of prescription benzodiazepines/Z-drugs and opioids.
引用
- Séguin DJ, Peschken CA, Dolovich C, et al. Polypharmacy and Potentially Inappropriate Medication Use in Older Adults With Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2022. PMID: 34369087. doi:10.1002/acr.24766
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。